Trial
NCT01353638
Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Christoph Aufricht
Collaborators
—
Condition
End Stage Renal Disease
Intervention
Dipeptiven (Alanyl-glutamine-dipeptide)
Why stopped
Primary endpoint (HSP) could not be analyzed with the specified method in the planned interim analysis; a method of increased sensitivity had to be established.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-09-11